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Abstract
Today there are many licensed antiviral drugs, but the
emergence of drug resistant strains sometimes
invalidates the effects of the current therapies used in
the treatment of infectious diseases. Compared to
conventional antiviral drugs, monoclonal antibodies
(mAbs) used as pharmacological molecules have
particular physical characteristics and modes of action,
and, therefore, they should be considered as a distinct
therapeutic class. Despite being historically validated,
antibodies may represent a novel tool for combatting
infectious diseases. The current high cost of mAbs’
production, storage and administration (by injection
only) and the consequent obstacles to development
are outweighed by mAbs’ clinical advantages. These
are related to a low toxicity combined with high
specificity and versatility, which allows a specific
antibody to mediate various biological effects, ranging
from the virus neutralization mechanisms to the
modulation of immune responses.
This review briefly summarizes the recent
technological advances in the field of
immunoglobulin research, and the current status of
mAb-based drugs in clinical trials for HIV and HCV
diseases. For each clinical trial the available data are
reported and the emerging conceptual problems of
the employed mAbs are highlighted.
This overview helps to give a clear picture of the
efficacy and challenges of the mAbs in the field of
these two infectious diseases which have such a
global impact.
Keywords: monoclonal antibodies, mAb-mediated
antiviral mechanisms, anti-infectious biological agents,
antiviral mAb based therapy, anti-HIV drugs, anti-HCV
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Introduction
The innate immune response is the first-line defense in
determining the outcome of an infection. Infectious
agents contain conserved motifs on their surface that
react with conserved pattern recognition Toll-like recep-
tors of the host. This interaction initiates a powerful
innate immune response. Moreover, the infectious
agent’s surface proteins and carbohydrates come into
contact with B-cell receptors, membrane-bound immu-
noglobulin of isotype M (IgM) or D (IgD), and often
induce potent antibody responses, which take some
weeks to fully develop [1].
When a vertebrate organism encounters a pathogen,
such as a virus or bacteria, it generates a polyclonal anti-
body response against numerous epitopes on different
antigens during infection; therefore, polyclonal serum con-
tains a large and diverse population of antibodies, which
also include neutralizing antibodies (nAbs). Thus, polyclo-
nal serum-derived biotherapeutic products can contain
various nAbs against multiple and distinct epitopes; these
nAbs provide strong protective activity due to additive or
even synergistic effects on neutralization. However, in this
type of product the vast majority of their constituent spe-
cific antibodies are non-neutralizing, since they are direc-
ted against misfolded protein or against epitopes on native
surface proteins for which antibody binding is not protec-
tive [2,3]. Furthermore, for some viral and bacterial infec-
tions, no correlates of protection have been established;
therefore, the significance of antibody titers, apart from
indicating past exposure, is not clear.
Mechanisms of immunological escape can explain why
total antibody titers are not always protective. Many
infectious organisms, including viruses, can constantly
mutate surface proteins and exploit glycans to shield
important epitopes, diverting the antibody response away
from functionally important epitopes in favor of immu-
nogenic irrelevant epitopes [4].
Thanks to their protective properties, the administra-
tion of hyperimmune sera from immunized animals or
immune human donors, named ‘serum therapy’, was the
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first effective treatment of infectious diseases. Later, the
advent of antibiotic therapy with the advances in vaccine
design has meant that serum therapy was almost aban-
doned for many infectious diseases. Nevertheless, hyper-
immune human sera immunoglobulin preparations are
still used to treat different bacterial toxins and virus
related diseases, including those caused by cytomegalo-
virus (CMV), respiratory syncytial virus (RSV), hepatitis
A virus (HAV), hepatitis B virus (HBV), rabies, vaccinia,
vesicular stomatitis virus (VSV) and measles, underscor-
ing the fact that antibody therapy remains an effective
means of treatment [5,6].
Today, the ability to rapidly generate and manipulate
antibodies with a defined epitope recognition, named
“monoclonal antibodies” (mAbs) (Figure 1), has opened a
new window of opportunity for a rematch of antibodies in
clinical practice. This achievement has been possible
thanks to advances in cellular biology and biotechnology
(Figure 2), and also to improved purification techniques
which have made these therapeutics safer, less immuno-
genic and more effective. MAb preparations have many
advantages over immune sera-derived preparations which
can vary due to both time and the source of origin, since
different hosts mount different antibody responses. One
advantage is that mAbs, by virtue of the fact that they are
chemically defined reagents, exhibit relatively low lot-to-
lot variability and low risk of pathogen transmission.


















Figure 1 Schematic structure of a mAb. All immunoglobulins are composed of two identical light (L) chains and two identical heavy (H)
chains, linked by disulphide bonds (black dashed bars). The heavy chains contain one variable domain (VH) and three or four constant domains
(CH1, CH2, CH3 and CH4) depending on antibody isotype. By contrast, the light chains contain only one variable domain (VL) and a single
constant domain (CL). Within the Fab region, at the end of the two arms of the Y-shaped molecule, the variable domain of a heavy chain pairs
with the light chain variable domain to form the antigen-binding site. In more detail, within the matched V regions, three short polypeptide
segments on the heavy chain and three on the light chain form the complementarity-determining regions (CDRs), which dictate the precise
antigen-binding characteristics of the antibody. On the other end, the Fc domain, which includes the sites for interaction with the complement
system and Fc receptors, mediates effector functions determining the fate of the bound antigen.
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greater activity per mass of protein since all the Ig mole-
cules are specific for the desired target. This phenomenon
is illustrated by the report that two 0.7 mg doses of two
mAbs provided the same protection against tetanus toxin
as 100 to 170 mg of tetanus immunoglobulins [7]. Neither
does mAb therapy have the immunological complications
associated with the use of heterologous sera in humans,
such as serum sickness and immediate hypersensitivity,
which significantly limited the latter’s usefulness [8].
In recent years, mAbs have emerged as a new class of
biological drugs in oncology as well as in immune and
inflammatory diseases, albeit their development in infec-
tious diseases has been slower. To date, the only mAb
approved in this field is palivizumab, an anti-RSV mAb
licensed for prevention of severe respiratory disease in
high-risk infants and immunocompromised adults. Now
the scenario is gradually changing and there are many
antibodies against viruses and bacteria in various stages
of clinical development. This trend has also been influ-
enced by the development of different scientific disci-
plines, which makes it possible to study and dissect the








































































Figure 2 Evolution of mAbs linked to the need to decrease their immunogenicity. Different methods to obtain mAbs are depicted. Mouse
mAbs, the ‘hybridoma’ cells derived from the stable fusion of immortalized mouse myeloma cells with lymphocytes from immunized mice, are
screened to identify individual clones producing identical antibody to a single antigenic determinant [118]. Chimeric mAbs, the murine constant
regions of both heavy and light antibody chains (mCH and mCL), are replaced with human counterparts (hCH1, hCH2, hCH3 and hCL1), leaving
intact the murine variable portions (mVH and mVL) [119]. Humanized mAbs, only the CDRs of the murine mAbs (mCDRs) from both the mVH
and the mVL, are ‘grafted’ into a human backbone antibody [120,121]. Human mAbs, 1)Human memory B-cells isolated from patients are
immortalized by Epstein Barr Virus (EBV) and CpG oligodeoxynucleotide, and then screened for specific antibody production [122]. 2) Transgenic
mice, obtained by a genetic replacement of the mouse immunoglobulin genes with human counterparts, are used to obtain fully human mAbs
by traditional hybridoma technology [123]. 3) Antibody libraries, constructed by in vitro combinatorial assembly of human immunoglobulin
variable-region gene (V genes) and cloned to provide the display onto phage surfaces, are subjected to a panning against an antigen in order
to select specific clones [124]. The first mAbs of each category approved for clinical use are shown. Palivizumab is the first and, so far, only mAb
approved for infectious diseases. The endings used to name the different types of mAbs are also indicated.
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the development of more targeted drugs. There are
excellent reviews about this topic [6,9].
In this review we focus on the mAb-therapies now
underway in clinical trials (Table 1) designed for human
immunodeficiency virus (HIV) and hepatitis C virus
(HCV) infectious diseases. Both these worldwide epi-
demics require new strategies due to the lack of a defi-
nitive cure and effective vaccines, to the continuous
emergence of drug resistant variants, to the toxicities of
licensed drugs and to the need to ensure a treatment for
all patients. In this context, antibodies represent an
intriguing alternative as therapeutics; in their favor are
their different resistance mechanisms and a more favor-
able toxicity profile when compared to other available
drug classes, fitting them for use in conjunction with
the current chemotherapy by slowing the onset of resis-
tance and possibly enhancing therapeutic efficacy.
MAbs-mediated clearance of viruses and infected cells
The antibody structure comprises a pair of identical heavy
and light chains linked by disulphide bonds held in a Y-
shaped arrangement (Figure 1). The fragment antigen-
binding (Fab) portion, the region that binds the antigen, is
composed of one variable and one constant domain of
both the heavy and the light chain. The remaining con-
stant sections of the longer heavy chains form the tail of
the Y, termed the crystallizable fragment (Fc) region,
which provides the signal for effector functions.
Antibodies can provide protective effects through var-
ious mechanisms [10]. Viral neutralization is generally
meant as the ability of an antibody to provide sufficient
steric interference to disrupt the interaction between a
microbic antigen and its ligand in experimental condi-
tions in vitro. This activity is clearly associated with pro-
tection, thanks to their Fab domain alone, both in
natural infection and after immunization. Virus infection
includes sequential steps beginning with attachment to
cell-surface receptors and ending with delivery of the
viral genetic material into the cytoplasm [11]. Fusion of
viral and cellular membranes is a basic entry mode for
enveloped viruses, such as HIV and HCV [12], which
still differ in specific aspects of viral entry and assembly,
thus offering unique therapeutic opportunities. The cell
surface is certainly more directly accessible for the
Table 1 Anti-HIV and HCV mAbs in clinical development.
Compound Target Origin Company Indication
















Prevention of HIV infection Phase I















Therapy of HIV infection Phase I
MBL-HCV1 Anti-E2 Human
mAb
MassBiologics Prevention of liver reinfection with HCV after transplantation Phase
II
MAbs against host antigens
IBALIZUMAB Anti-CD4 receptor Humanized
mAb
TaiMed Biologics/Tanox Therapy of HIV infection Phase I/II
PRO-140 Anti-CCR5 receptor Humanized
mAb
Progenics/PDL Therapy of HIV infection Phase I/II
CCR5mAb004 Anti-CCR5 receptor Human
mAb





Peregrine Pharmaceuticals Therapy of HIV/HCV co-infection
Phase II








Pfizer Therapy of HIV infection Phase I
(study withdrawn prior to
enrollment)
Therapy of advanced HCC in
HCV infected patient Phase II
CT-011 Anti-PD-1 Humanized
mAb







Therapy of chronic HCV infection Phase I
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action of the antibodies; therefore, the phase of virus
entry is one of the most important targets in preventing
viral infection at the origin, and many known nAbs act
at this step. For the same reason, inhibition of the
release of progeny virus is another possible mechanism
of neutralization, as demonstrated by antibodies directed
against influenza A virion surface neuraminidase [13]. In
HIV and HCV fields, no virus release inhibiting antibo-
dies have been identified to date.
The interaction of HIV envelope surface protein
gp120 with its host receptor, CD4, on human T cells
triggers conformational changes in the envelope, result-
ing in exposure of a transient binding site for co-recep-
tor CCR5 or CXCR4. This in turn promotes additional
conformational changes in virus gp41 protein which
allow it to insert its fusion peptide into the target cell
membrane to initiate membrane fusion and viral entry
into host cells. NAbs can inhibit viral infection by sev-
eral different mechanisms in parallel with the steps that
allow the viruses to enter into cells (Figure 3). They can
directly block virus attachment to target cells by inter-
fering with virus-receptor interactions, as in the case of
nAbs against the CD4-binding site on HIV gp120 [14].
This same goal can also be achieved by directing the
antibodies to the virus receptor and/or co-receptor on
host cells. MAbs can also block fusion at the cell mem-
brane at the post-binding/pre-fusion stage, as exempli-
fied by anti-CD4 [15] and/or anti-CCR5/CXCR4 (CC-
motif receptor 5/CXC-motif receptor 4) mAbs, under
development [16]. Again, mAbs directed to the external
proximal membrane region of HIV gp41 can interfere
with conformational changes needed for membrane
fusion [17].
Unlike HIV, HCV entry into target cells occurs via
clathrin-mediated endocytosis of the viral particle [18].
Subsequent release of the viral genome into the cytosol
requires the pH-dependent fusion of viral and cellular
membranes. Current models suggest that HCV circulate
as LipoViral-Particles (LVPs) in the vascular system,
these consisting of lipoproteins in complex with virus
particles. Following localization to the surface of hepato-
cytes through interactions of LVPs with glycosaminogly-
cans and the low density lipoprotein receptor, specific
binding of the E1 and E2 virus surface glycoproteins
with the host SR-B1 scavenger receptor and CD81 occur
[19]. Subsequently, viral particles are translocated to
regions of the membrane possessing tight junction pro-
teins occludin and claudins; the binding to these recep-
tors results in clathrin-mediated endocytosis. As for
HIV, mAbs directed against spike viral proteins, as well
as against host receptors, may act at an early stage of
infection by preventing the binding of the virus on the
cell surface. For example, antibodies recognizing the
CD81-binding site within the envelope glycoprotein E2
have been shown to block viral entry, as have a number
of anti-receptor antibodies targeting CD81 [20,21] and
SR-BI [22]. Some antibodies may act by blocking con-
formational changes and/or the requisite interactions
between the viral and endosomal membranes required
for fusion; although as yet no fusion determinant within
the envelope glycoproteins has been defined.
Host protection in vivo is more complex and involves
the interaction of antibodies with cells and molecules of
the innate immune system. The antibody can exert pro-
tective actions through an Fc region-mediated recruit-
ment of other components of the immune system,
including antibody-dependent cell-mediated cytotoxicity
(ADCC), complement-dependent cytotoxicity (CDC)
and antibody-dependent cellular phagocytosis. Receptors
for the Fc segment of IgG (Fcy receptors; FcgRs) are
expressed on the surface of different types of cells,
including natural killer cells (NK), monocytes, macro-
phages, dendritic cells and neutrophils. With the excep-
tion of gδT cells, FcgRs are not normally found on T
lymphocytes. Similarly, the receptor for Fc segment of
IgA, the FcaR, involved in phagocytosis and induction
of microbe killing, is expressed on monocytes, macro-
phages and neutrophils [23].
The ADCC process is triggered by the interaction
between the Fc region of an antibody bound to a non-
self antigen exposed on host cells, and the Fc receptors
on immune effector cells. The subsequent release of
cytokines and cytotoxic granules containing perforins
and granzymes promotes the death of the target cell.
CDC is initiated by complement component C1q bind-
ing to the Fc region of IgG, which is in turn bound to
the foreign antigen on the cell surface. This triggers a
proteolytic cascade to activate the complement, so lead-
ing to the formation of a membrane attack complex that
kills the target cell by disrupting its cell membrane. The
Fc region can also mediate complement binding to and
deposition on free virions, which can cause a direct viro-
toxic effect or inhibit virus binding to cells. Moreover,
the so-called opsonization process, consisting of the
binding of antibody Fab portion to the antigen following
by the interaction of Fc domain to an Fc receptor on
phagocytes, is a powerful mechanism to enhance the
phagocytosis [9].
With respect to HIV, a potential role for ADCC in
modulating the course of HIV infection was first pro-
posed on the basis of studies showing an inverse asso-
ciation between ADCC antibody levels and the clinical
stage of disease. The strongest evidence for a role for
ADCC antibody in disease progression comes from a
study by Baum et al. of the Multicenter AIDS Cohort
Study [24]. In that study, rapid progressors had signifi-
cantly lower ADCC antibody titers against CEM. NKR
cells coated with gp120 than did non-rapid progressors
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at corresponding visits or non-progressors at any visit.
Morever, HIV-infected individuals with spontaneously
undetectable viremia were shown to have higher ADCC
antibody levels than viremic subjects [25].
In the context of HCV infection, Fc-mediated effector
functions, although less well understood, can still have an
important role. Sera from both the acute and chronic
phase of infection can mediate ADCC via binding to viral
protein E2 expressed at the cell surface [26], while several
E2-specific mAbs are able to induce CDC of E2-expressing
cells [27]. Optimizing non-nAb effector functions, such as
ADCC, CDC and fagogocytosis, may prove critical in the
design of new effective anti-HCV therapeutic antibodies
[28].
Modulation of immune response by mAbs in order to
overcome exhaustion in chronic viral infections
Many viruses, including HIV and HCV, have developed
mechanisms for evasion and/or modification of the host’s
innate and adaptive immune response, often causing per-
sistent viral infection. One of the most extensively investi-




































Figure 3 Possible mechanisms of action of the mAbs with antiviral properties. Panel A shows a hypothetical viral life cycle, highlighting
potential points for therapeutic antiviral mAbs. Antibodies can block receptor engagement by binding to specific virus surface proteins (1), as
well as by binding to the viral receptor or co-receptor on host cell surface (2). Some antibodies, can neutralize viral infection through interfering
with conformational changes required for membrane fusion and subsequent release of the viral core into the target-cell cytoplasm; this post-
binding neutralization may occur at the cell surface (3), or inside the endosomes for the viruses (for example, HCV) whose entry into the cell
requires an endocytosis step (4). Antibodies recognizing viral or host proteins expressed on infected cell surface can exert protective actions
through the Fc-mediated effector functions (for example, CDC, ADCC) (5). Again, mAbs may prevent the release of progeny virions (6). At the
bottom the antibody neutralizing effects on the viruses before cell binding, including the direct virolysis by CDC and the mAb-mediated
enhanced phagocitosis, are shown (7). In Panel B, the possible mAb-mediated immunomodulary therapies are depicted. In some chronic viral
infections, virus-specific immune cells may persist in a ‘non-functional’ state, because of an imbalance of immunoregulatory signals involving
multiple inhibitory and activating receptors, triggered by soluble factors and/or cell surface ligands. Therapeutic approaches using specific mAbs
to block host immunosuppressive molecules (antagonism) or to trigger activating receptors (agonism) may be a valid strategy to restore
immune cell function and treat various chronic viral infections.
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system is the exhaustion of virus-specific T cells. Exhaus-
tion consists of a progressive dysfunction characterized by
the inability to proliferate and to produce key antiviral and
immune stimulating cytokines (for example, interleukin
(IL)-2, tumor necrosis factor (TNF)-a, interferon (IFN)-g),
or to lyse infected cells [29].
A feature of functional exhaustion is that it affects many
antiviral properties of both mouse and human CD8+ T
cells. Loss of effector functions proceeds in a hierarchical
manner starting with defects in IL-2 production and pro-
liferation, followed by the decrease of TNF production.
Cytotoxic activity is also lacking in exhausted human CD8
+ T cells. At a severe stage of exhaustion, IFN-g produc-
tion is eventually compromised, with exhausted T cells
ending up deleted if the high antigenic load persists [30].
Exhaustion can also occur in CD4+ T cells in both mice
[31] and humans [32]. Probably the best explanation for
this progressive dysfunction and loss of effector T cells is
the continuous triggering of virus-specific T cell receptors
owing to a high antigenic load in persistently infected
hosts without a critical rest period. The current consensus
is that functional exhaustion is a way of limiting the mag-
nitude of effector T cell responses. Although this may
safeguard against autoimmune responses, it may also com-
promise effective immunity against persistent infectious
agents and tumors [29].
Exhausted T cells are subject to complex layers of nega-
tive regulation. This involves signaling through multiple
inhibitory receptors that inhibit functional and prolifera-
tive responses. The CD28 family member programmed
cell death 1 (PD-1) has been shown to be the most highly
expressed inhibitory receptor on CD8+ T cells during
chronic infection, and to have a major role in regulating T
cell exhaustion during infection [33,34]. Increased expres-
sion of PD-1 by T cells also occurs during HBV and HCV
infections [35-37]. Several other inhibitory receptors have
also been shown to induce T cell unresponsiveness during
chronic infections. These receptors include cytotoxic T
lymphocyte antigen 4 (CTLA-4) [31,38,39], T cell immu-
noglobulin domain and mucin domain protein 3 (TIM3)
[40,41], and lymphocyte activation gene 3 (LAG-3) [38]. In
addition, certain cytokines, such as IL-10 and transforming
growth factor-b (TGFb) as well as regulatory T cells, may
also contribute to the lack of T cell functionality during
situations of high antigenic burden [42].
There is intriguing evidence that blockade of the inhi-
bitory receptor could restore antigen T cell responses.
For example, blockade of the PD-1 signaling pathway
improves antigen-specific T cell proliferation and cyto-
kine secretion in lymphocytic choriomeningitis virus
(LCMV)-infected mice [31,34] and in humans with
chronic HIV [32,43,44], HBV [45] and HCV [36] infec-
tions. This effect was synergistically improved in LCMV
infected mouse following the simultaneous blockade of
the T cell inhibitory receptors PD-1 and LAG-3, thanks
to which a diminished viral load in vivo was observed,
although blocking LAG-3 pathway alone had little effect
on the severity of exhaustion [34]. Moreover, mAb-
mediated blocking of CTLA-4 pathway in vitro aug-
ments HIV-specific CD4+ T-cell function suggesting
that the immune modulation of this target may also
provide a clinical benefit in infected individuals [39].
Another example is the manipulation of signals
mediated by glucocorticoid-induced TNF receptor
(GITR), a recently identified member of the TNF recep-
tor superfamily, preferentially expressed on subset CD4
+CD25+ regulatory T cells. GITR signals break the sup-
pressive activity of this subset. In fact, an agonistic anti-
GITR mAb immediately injected after viral infection sig-
nificantly increased the number of activated CD4+ and
CD8+ T cells secreting IFN-g [46].
One must remember that the manipulation of immu-
nological responses could have detrimental effects on
the host, as highlighted by the recent tragic human trial
of TGN1412. This is a mAb against human T cell co-
stimulatory molecule CD28 developed by TeGenero to
treat B-cell chronic lymphocytic leukaemia, autoimmune
and inflammatory diseases, on the basis of its capability
of inducing preferential activation and expansion of
immunosuppressive regulatory T (Treg) cells, as
observed in rodent models. TGN1412 has been termed
a ‘superagonist’ because it binds to CD28 and activates
T cells without the need for prior T cell antigen recep-
tor (TCR) signaling. In a Phase I clinical trial (in March
2006), following administration of TGN1412, six healthy
young men suffered a life-threatening cytokine-release
syndrome (CRS) involving multi-organ failure, some-
thing unpredicted by the preclinical studies. It is now
clear that in the presence of TGN1412, activated CD4+
effector memory T (TEM) cells were the source of the
cytokines that mediated the CRS observed in the volun-
teers. Treg cells were not able to prevent systemic
inflammation, probably because the balance between
activated Treg cell and TEM cell numbers is disadvanta-
geous for humans compared with laboratory rodents.
Furthermore, in macaques, but not in humans, CD4+ T
cells lose CD28 expression during their differentiation
into TEM cells; this detail, however, had gone unnoticed
despite many years of primate testing. In conclusion,
this model failed to prevent the disastrous case above
[47].
In view of these events, such a risk needs to be care-
fully assessed if the modulation of immune inhibitory or
activating receptors is used for increasing the functional
activity of virus-specific T cells in order to avoid non-
specific inflammation. These therapeutic approaches are
being carefully evaluated for cancer as well as for HIV
and HCV chronic viral disease.
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Clinical development of anti-HIV and HCV mAbs
MAbs against viral antigens
Given the potential antiviral effect of the antibodies,
viruses have evolved multiple mechanisms to protect
themselves from antibody binding. One of these, the viral
receptor glycosylation, is widely shared among different
viruses. Carbohydrates are poorly immunogenic and,
therefore, do not stimulate the response of type B lympho-
cytes and simultaneously hide the underlying protein
structures. HCV E2 protein contains up to 11 potential N-
linked glycosylation sites. Specific glycans mask the CD81-
binding site and, therefore, nAb epitopes [48]. Lipid
shielding may represent an additional strategy used by
HCV to evade the antibody response. Current data suggest
that key neutralizing epitopes are less accessible on LVPs.
More recently, HCV has been found capable of direct cell-
to-cell transmission, which is largely resistant to antibody
neutralization [49,50]. HIV envelope protein is also glyco-
silated and changes occur in the frequency and position of
glycans HIV gp120; these ‘evolving glycan shields’ have
been shown to decrease sensitivity to antibody neutraliza-
tion [51]. Other factors of antibody escape for HIV are: tri-
merization of the gp 120 and gp 41 that can shield
vulnerable epitopes better exposed on the individual
monomeric subunits; kinetic and spatial constraints that
impede antibodies from accessing potentially vulnerable
sites during receptor binding and membrane fusion pro-
cess; the variable loops of gp120 that are a prime target for
nAbs, which usually have a very narrow breadth of reactiv-
ity [52]. Finally, the high mutation rate of many viruses,
including HIV and HCV, which undergo rapid antigenic
variation, allows them to escape neutralization, constitut-
ing a significant hurdle for nAbs development.
All these problems may be counter-balanced by select-
ing nAbs which target conserved and more accessible
areas of viral particles, and/or by using mixtures of nAbs
which target various key epitopes. In fact, it has been
demonstrated that combination therapy with mAb cock-
tails prevents escape variants for many viruses, including
influenza [53], coronavirus [54] and LCMV [55], and that
broad neutralization in the sera of most of some indivi-
dual HIV infected donors can be associated with single
or four to five principal specificities [56].
Recent studies have indicated that nAbs play a critical
role in HCV disease outcome. Viral clearance was asso-
ciated with a rapid induction of neutralizing antibodies in
the early phase of infection with some evidence that these
antibodies are broadly reactive [57,58]. In contrast, chronic
HCV infection was characterized by absent or low-titer
neutralizing antibodies in the early phase of infection and
the persistence of infection, despite the induction of cross-
neutralizing antibodies in the later phase of infection. Cur-
rent understanding of the nAb response raised against
HCV suggests that E2 is the major target, and that
multiple epitopes within E2 may be targeted by both lin-
ear-and conformation-dependent antibodies. Predomi-
nantly, these neutralization epitopes overlap with CD81-
binding sites and clearly demonstrate a role in inhibition
of entry. Currently, one of these mAbs, MBL-HCV1, is
being investigated in clinical trials in the prevention of
liver re-infection after transplantation, for which novel
antiviral preventive and therapeutic strategies are urgently
needed. In fact, re-infection of the graft is universal, being
characterized by accelerated progression of liver disease;
IFN-based therapies exhibit enhanced adverse effects and
limited efficacy in these patients [59,60]. MBL-HCV1 is a
fully human monoclonal antibody isolated from transgenic
mice and directed to a highly conserved linear epitope of
HCV E2 glycoprotein. It is able to neutralize pseudo-
viruses from multiple HCV genotypes and has demon-
strated efficacy in preventing HCV genotype-1 infection in
HCV naïve chimpanzees. A phase I open-labeled, dose
escalation study was performed in healthy adult volunteers
starting with 1 mg/kg and escalating to 3, 10, 30 and 50
mg/kg after a 10-day post-infusion safety review. MBL-
HCV1 was well-tolerated without any seriously adverse
effect event. Based on the favorable safety, tolerability and
pharmacokinetics data, a phase II study of MBL-HCV1 in
chronically infected HCV patients undergoing liver trans-
plantation has been planned [61].
In the context of HIV disease, despite intensive study
over two decades, only a small number of broadly neu-
tralizing mAbs have been identified from infected
patients and little is known about their activity in vivo.
These antibodies are able to inhibit viral entry of most
primary HIV isolates in vitro [17,62-64] and the excep-
tionally high level of mutation found in their genes may
reflect chronic immune responses to HIV and persistent
hypermutation and selection [65]. A number of trials
evaluating different formulations of anti-HIV monoclo-
nal antibodies are now in progress.
The first trial assessed a chimeric monoclonal antibody
CGP 47,439 to the V3 loop of the HIV-1 envelope gp120
over 21 weeks [66,67]. Subsequent studies evaluated the
kinetics of monoclonal antibody F105 directed to the
CD4-binding site of gp120 [68,69], a humanized antibody
binding to the V3 epitope GPGRAF [70]. Finally, a huma-
nized mAb, KD-247 is under evaluation in clinical trials.
Its epitope was mapped to 6 aa, IGPGRA, at the tip of the
V3 loop of Envelope protein and demonstrates cross-
neutralizing activity against HIV-1 isolates in clade B [71].
A drug based on the mAb cocktail mode is also cur-
rently in clinical development. In this regard it has already
been observed that in HIV neutralization assays the effec-
tiveness of a mix of broadly neutralizing antibodies
increased synergistically compared to the effect of the indi-
vidual antibody. The synergy effect was relatively weak,
with a maximum of two- to four-fold enhancement,
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between antibody pairs, thereby increasing neutralization
titers about 10-fold in triple and quadruple antibody com-
binations [72]. However, the use of antibodies in the cock-
tail mode, as an approach to improve their effectiveness, is
already recognized for other pathogens or toxins. In the
case of tetanus toxin, it has been reported that combining
the action of three out of four antibodies increased the
neutralizing activity up to 200 times [73]. In the case of
botulinum toxin, neutralizing activity has been reported
up to 20,000 times higher when using a mixture of three
monoclonal antibodies [74]. Instead, other studies have
demonstrated that the combination of two potent neutra-
lizing mAbs against HIV, VRC01 and PG9, although not
synergistic, can mediate additive neutralization viral activ-
ity and provides an improved neutralization coverage of
90% to 97% of viral strains by combining independent epi-
tope targeting [75].
In a proof-of-concept passive immunization trial with
humans, it has been demonstrated that a cocktail of the
three broadly neutralizing mAbs - 2G12, 4E10 and 2F5 -
was able to delay viral rebound in patients whose infec-
tions were fully suppressed by antiretroviral treatment
before administration of the antibodies [76]. Interestingly,
the main antiviral effect observed was primarily attributa-
ble to the 2G12 antibody, a mAb that binds to a non-
continuous epitope composed of glycosylation residues
distributed over the envelope protein gp120 [64], whereas
the other two mAbs, 4E10 [77] and 2F5 [78], recognize
two adjacent highly conserved epitopes on the mem-
brane-proximal ectodomain of the HIV-1 envelope pro-
tein gp41. In earlier phase I clinical trials, safety and
tolerability were demonstrated [79,80]. During a long-
term multiple dose phase II clinical trial, high doses of
the three neutralizing antibodies were given in combina-
tion to 14 HIV-1-infected individuals at weekly intervals
over three months. Pharmacokinetic analysis revealed
that repeated infusions at high dose levels were well tol-
erated by the patients and did not elicit an endogenous
immune response against the monoclonal antibodies.
The antibodies showed distribution and elimination
kinetics similar to those seen for other human-like anti-
bodies, though monoclonal antibody 2G12 had a signifi-
cantly longer elimination half-life (21.8 +/- 7.2 days) than
monoclonal antibodies 4E10 (5.5 +/- 2.2 days) and 2F5
(4.3 +/- 1.1 days) [81]. Furthermore, analyses of the
emergence of mutations conferring resistance to these
three mAbs were performed. Sequence analysis of the
2G12 epitope relevant N-glycosylation sites of viruses
derived from 13 patients demonstrated that mutations in
these sites are associated with resistance. In vitro selec-
tion experiments with isolates of four of these individuals
corroborated the in vivo finding that virus strains rapidly
escape 2G12 pressure. Importantly, in vitro selection
with 2F5 and 4E10 demonstrated that resistance to these
nAbs can be difficult to achieve and can lead to selection
of variants with impaired infectivity [82]. Moreover, gen-
eration of viruses resistant to the triple-combination was
a slower process characterized by recurrent loss of virus
replication; some generated triple-resistant viruses
seemed to be impaired in their replicative fitness, and
none of the patients developed detectable viruses that
escaped neutralization by all three mAbs within the 77-
day observation period [83].
As is true with all mAbs designed for infectious disease,
the development of a successful vaccine would reduce the
need for them. However, given the scarcity of drugs in the
field of virology and given the slow progress on the HIV
vaccine front, the development and use of microbicides,
compounds that could be applied topically to prevent HIV
transmission, is one of the possible strategies to counter
the spread of HIV. In this regard, mAbs could be proposed
as suitable components of microbicides to fight HIV entry
at mucosal surface. A safety study of P2G12 mAb adminis-
tered vaginally in healthy women has been completed.
P2G12 is the broadly neutralizing 2G12 mAb manufac-
tured from tobacco plants [84]. Most mAbs in clinical
trials have been produced using a system called Chinese
Hamster Ovary cell (CHO-Cell) fermentation [85], includ-
ing 2G12 used along with 2F5 and 4E10 antibodies as a
cocktail. The CHO-Cell fermentation production method
is very expensive and cannot produce enough mAbs on a
scale required for the global market; therefore, plant man-
ufacture of such mAbs may hopefully offer some solutions
to lower production costs and improve output. The pro-
cess yields five grams of purified antibody from 250 kg of
tobacco and production costs could be 10 to 100 times
lower than when using conventional bioreactors. This
study has been designed to confirm the safety of a vagin-
ally delivered mAb P2G12 derived from plants and manu-
factured to Good Manufacturing Practice (a quality
standard used for the manufacture of medicinal products).
The medicine is the first plant-produced antibody to be
greenlit for clinical testing by Britain’s Medicines and
Healthcare products Agency (MHRA). It took about a
year to get that agency’s stamp of approval because it
required assurances that the drugs did not contain aller-
genic plant sugars or pesticides. No matter how it is pro-
duced, P2G12 antibody has not been shown to actually
prevent HIV-1 infection in clinical trials; thus a version
made from tobacco plants would not see approval any
time soon. P2G12 would also likely be just one ingredient
in a cocktail of plant-produced antibodies [84].
MAbs against host receptors
To eliminate or reduce the development of escape var-
iants it has been proposed that targeting the conserved
cellular receptors of the virus may open new avenues for
a viable antibody therapy for HIV infection. HIV entry
into CD4+ T cells requires the presence of a co-receptor,
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either CCR5 or CXCR4, on the target cell. Thus, based
on this hypothesis, mAbs directed against CD4 and
against the co-receptor CCR5, have been developed and
are being analyzed in clinical trials.
CD4 functions as a co-receptor, physically associating
with the TCR during Ag recognition by binding to a non-
polymorphic component of the major histocompatibility
complex (MHC) class II molecules on the surface of the
antigen-presenting cell. Ibalizumab, a humanized mAb,
binds CD4 on T cell surface away from the binding site
for MHC class II molecules. It does not inhibit gp120
binding to CD4 but appears to exert its antiviral property
by post-binding conformational effects that prevent CD4-
bound gp120 from interacting with CCR5 or CXCR4
[19,86]. By contrast, other monoclonal antibodies, that
competitively inhibit gp120 binding, interfere with MHC
class II immune function [87,88]. The reported human
experience with Ibalizumab consists of three clinical trials.
During phase I study, it was observed that peak mean
reductions in viral load occurred later in the higher dose
cohorts, whereas the extent and duration of viral suppres-
sion correlated with the degree of CD4+ cell coating by
ibalizumab, which was maintained longer in the higher
dose cohorts, with a duration of 15 to 34 days. Peak
increases in CD4 counts at one day after infusion, well
before the peak declines in viral load; this suggests that the
increase may have been due to redistribution of CD4+
cells from lymphoid tissue rather than regeneration of
CD4+ cells in the setting of viral suppression. A multidose
study demonstrated continued safety over an extended
treatment period and provided data on the development
of ibalizumab resistance. Resistance testing showed
reduced susceptibility relative to baseline. Resistant isolates
remained dependent on CD4 for viral entry, suggesting
that resistance did not develop through the use of alterna-
tive receptors. Genotypic analysis was unable to identify
mutations, diagnostic of ibalizumab resistance. Consistent
with the allosteric mechanism of ibalizumab’s anti-HIV-1
effect, the development of resistance is associated with a
reduction in the maximum percentage inhibition rather
than the shift in the IC50 characteristic of competitive
inhibitors [89,90]. The half-life of IgGs under normal phy-
siological circumstances is two to three weeks [91]. In con-
trast, the average half-life of ibalizumab is 3 to 3.5 days
[89]. This is consistent with observations of other anti-
CD4 antibodies, in which internalization or shedding of
the receptor results in more rapid antibody degradation. A
randomized, double-blind, placebo controlled, phase IIa
study has evaluated the ibalizumab efficacy, the results
showing a considerable viral load reduction with respect
to the placebo arm [92].
CCR5 is a chemokine receptor that mediates activation
and migration of T cells and other leukocytes. CCR5-
using (R5) viruses typically mediate transmission and then
predominate through the progression to symptomatic dis-
ease. Viruses can use an alternative chemokine receptor,
CXCR4, either exclusively or in addition to CCR5. The
CXCR4-using virus can be present initially, but tends to
result in an increasing proportion of subjects in the later
stages of the disease [93]. CCR5 co-receptor antagonists
represent an emerging antiretroviral treatment class and
the first to target a host molecule.
Currently, two anti-CCR5 mAbs are being investi-
gated. One of these is CCR5mAb004, a fully human
IgG4 monoclonal antibody with robust activity against a
diverse panel of HIV-1 isolates; it synergizes in vitro
with other ARV classes and appears safe and effective in
reducing HIV viral load. High levels of receptor occu-
pancy were observed for 14 to 28 days with the highest
dose cohorts, suggesting the potential for weekly, fort-
nightly or even monthly dosing [94].
The other anti-CCR5 mAb is PRO 140, a humanized
mAb that also synergizes with small-molecule CCR5
antagonists in laboratory studies [95]. PRO140 is being
investigated in two modes of administration: the classi-
cal intravenous (IV) form, and subcutaneous (SC) form.
The trial involving SC administration is the first to bear
the proof of concept for a mAb administered subcuta-
neously in HIV-1 infected subjects as a potent and long-
acting antiretroviral agent.
An IV form of PRO 140 tested as monotherapy in
HIV-1 subjects with only R5 virus detectable [96]
demonstrated potent and prolonged antiviral activity,
with a 1.83 log10 mean reduction in HIV-1 RNA and
safety relative to placebo. The successive randomized,
double-blind, placebo-controlled IIa trial examined the
antiviral activity, tolerability and pharmacokinetics of
single intravenous infusions of up to 10-mg/kg of mAbs.
All PRO 140-treated subjects treated with 10 mg/kg
experienced a 1-log10-unit reduction in HIV-1 RNA
level, there being just one exception; a post-study analy-
sis using the enhanced-sensitivity Trofile assay deter-
mined that this subject had dual/mixed virus at
screening. There was no change in co-receptor tropism
or emergence of PRO 140-resistant virus during the
course of this study, supporting the view that PRO 140
broadly inhibits R5 HIV-1 with a high barrier to resis-
tance. The maximum tolerated dose of IV PRO 140 has
not been determined, suggesting a sizeable margin of
safety for PRO 140 SC administration study [97].
The study involving PRO 140 SC administration
showed virologic suppression between successive doses
and no changes in R5 viral susceptibility to PRO 140
following three weeks of monotherapy, indicating no
adaptation of virus to use CCR5 in the presence of
drug. Pharmacokinetic data suggest the possibility of a
drug regimen administered fortnightly for HIV infected
individuals. Proteins and other macromolecules drain
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from SC sites into both blood capillaries and the lym-
phatic system. In animals, proteins with molecular
weights of greater than 16,000 daltons have been
observed to drain primarily into the lymphatic system
following SC administration [98]. Such proteins transit
through lymph fluid and typically are not absorbed sig-
nificantly into the blood until they reach the thoracic
duct. Since the molecular weight of PRO 140 is approxi-
mately 150,000 daltons, a substantial amount of SC
PRO 140 can be expected to drain into the lymphatic
system and potentially encounter CCR5+ cells in lym-
phoid tissues prior to reaching the bloodstream. For
these reasons, serum concentrations may not provide a
full picture of the overall exposure following SC dosing
of PRO 140. SC infusion is currently used by individuals
with primary immunodeficiency to self-administer at
home significantly larger amounts (approximately 11
grams) and volumes (approximately 70 mL total, up to
15 mL/site) of the weekly SC-administered immunoglo-
bulin [99]. Self-administration of 324 mg SC PRO 140
would be much simpler in comparison. Therefore, SC
PRO 140 offers the potential for significant dose-depen-
dent HIV-1 RNA suppression and may offer greater
convenience for many patients in terms of patient self-
administration [100].
The SC injection mode was chosen in order to evalu-
ate PRO140 safety and efficacy as an adjunct to an oral
antiretroviral regimen in HIV-infected injection drug
users with viral rebound and documented poor adher-
ence to the previous antiretroviral regimen. Therefore, a
phase IIb, national, multicenter, randomized, double-
blind, placebo-controlled study was initiated and is cur-
rently recruiting participants. Given the complications
that arise from the occurrence of drug resistances, the
use of antibodies together with combined therapy
increases the drug number and, therefore, the therapeu-
tic opportunities. In particular, in the case of CCR5
inhibitors, one report has demonstrated that resistance
to CCR5 inhibitors may increase the sensitivity of the
resistant virus to certain neutralizing antibodies [101].
Compared to CCR5, CXCR4-based blocking agents as
therapy against HIV are less attractive due to the crucial
role of CXCR4 in many biological processes, and the
absence to date of known naturally occurring mutations
leading to the inactivation of CXCR4 gene in humans.
Moreover, one major problem is linked to the fact that,
whereas R5 viruses are found on their own in 50% or
more of patients, viruses that using CXCR4 co-receptor
(X4) usually are present mixed together with R5 viruses;
therefore, the use of CXCR4 specific mAbs could result
in only little or transient effect on the overall viremia,
also complicating the evaluation of pharmacological
activity. However, antibodies against CXCR4 might still
provide some benefits for some HIV positive patients
when co-administrated with CCR5 antagonists, if the
safety of such combinations is established [93].
There is a pressing need for antiviral agents that are
effective against multiple classes of viruses. Broad specifi-
city might be achieved by targeting phospholipids that
are widely expressed on infected host cells or on viral
envelopes. Phosphatidylserine (PS), the most abundant
anionic phospholipid of the plasma membrane, is segre-
gated at the inner leaflet of the plasma membrane of rest-
ing mammalian cells. Loss of PS asymmetry occurs
during apoptosis, cell injury, cell activation and malig-
nant transformation, and results from inhibition of the
translocases or activation of PS exporters, or lipid scram-
bling enzymes, such as scramblases. After enveloped
viruses replicate within the host cell, they create their
‘envelope’ by carrying along part of the host cell’s mem-
brane upon exiting. As a result, the target phospholipid
becomes exposed on the surface of the virus as well as on
the infected host cell [102].
Bavituximab is the first in a new class of patented anti-
body therapeutics that target and, preferentially bind, to
these exposed phospholipids. It has demonstrated broad
therapeutic potential across multiple oncology indications
and represents a new approach to treating viral disease,
too. Bavituximab is currently being evaluated in rando-
mized phase II clinical trials for non-small cell lung cancer
and pancreatic cancer, for therapy of chronic HCV infec-
tion and for HIV/HCV co-infection. The therapeutic effect
of bavituximab appears to be due to ADCC of tumor and
virus-infected cells. Since PS exposure is an early event
during virus infection, ADCC may limit virus spread.
Furthermore, in the infectious disease setting, bavituximab
causes opsonization and clearance of infectious virus from
the bloodstream, leaving less virus to infect other tissues.
Three completed phase I HCV clinical trials have shown
that bavituximab is generally safe and well-tolerated.
Reductions in serum HCV RNA levels were also observed.
A randomized phase II clinical trial with previously
untreated HCV genotype-1 infected patients was designed
to determine the early virologic response (EVR) rate after
12 weeks of therapy with bavituximab in combination
with the antiviral drug ribavirin and safety profile versus
pegylated IFN-a-2a and ribavirin. The results show that
the combination of bavituximab with ribavirin has a better
safety profile than an IFN-containing regimen. However,
the EVR development in the bavituximab-containing arm
was later than the IFN-containing group; therefore, a
longer-term evaluation is needed to adequately compare
their effectiveness. In addition, the lower dose level
appears to be more active in HCV patients than the high
dose does. Such results suggest that future studies evaluat-
ing longer bavituximab treatment durations at or around
the lower dose level in combination with ribavirin and
potentially direct acting antivirals in certain patient
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populations may hold promise as IFN-free HCV therapeu-
tic regimens [103].
Targeting PS on cells infected with multiple different
viruses and on virions themselves is a promising anti-
viral strategy. Although resistance has developed in
monotherapy trials with ibalizumab (an anti-CD4 anti-
body), host-derived antigen, such as anionic phospholi-
pids, on virus-infected cells are independent of the viral
genome and as a consequence the acquisition of drug
resistance should be theoretically less problematic than
with agents that target virus-encoded components.
Immunomodulatory mAbs
Since the discovery of PD-1 as an inhibitory receptor asso-
ciated with T-cell dysfunction, the roles of various inhibi-
tory receptors on virus-specific CD8+ T cells have been
extensively studied in human chronic viral infections, such
as HCV, HBV and HIV infections. As blocking the inhibi-
tory receptors in vitro restores the functions of virus-speci-
fic T cells, novel HIV and HCV treatments based on
blockade of several immune checkpoint molecules are
being investigated. In particular, mAbs interfering with
two major inhibitory networks of the B7:CD28 family,
namely the PD-1 and CTLA-4 pathways [104], are cur-
rently being studied in clinical trials, to evaluate their
safety and efficacy. These mAbs recognize the PD-1 or
CTLA-4 receptor and neutralize the binding with their
respective ligands.
The PD-1:PD-L1 pathway delivers inhibitory signals
which regulate T cell activation. As a result it performs a
key role in various processes, namely in multiple tolerance
checkpoints that prevent autoimmunity, in the suppressive
tumor microenvironment, in the immune-mediated tissue
damage, in host defenses aimed at eradicating microbial
pathogens and tumors and finally, in T cell exhaustion
that contributes to both lack of viral control during
chronic infections and to T cell unresponsiveness [105]. In
cancers, a strong correlation between increased PD-L1
expression on tumors and a negative survival prognosis in
patients has already been observed. Various studies indi-
cate that mAbs targeting the PD-1 signaling pathway rein-
vigorate antigen-specific T-cell responses and promote an
immune response to fight tumors [106]. In HCV infection
the relationship between the PD-1 expression and the out-
come of the acute HCV infection was questioned; subse-
quently, recent studies have shown that the progression of
acute HCV infection to the chronic stage is associated
with a high level of PD-1 on HCV-specific CD8+ T cells,
whereas the clearance of HCV infection is associated with
lower levels of PD-1 expression [36].
Given these premises, MDX-1106, a fully human anti-
body also known as ONO-4538, and CT-011, a humanized
antibody, both interacting with PD-1 receptor, are being
developed as a treatment for cancer disease and for ther-
apy of chronic HCV infection [107]. To date, most clinical
experience with PD-1 blockade has been gained with
MDX-1106 in the tumor setting. Drug-related grade 3 or
4 toxic effects occurred in 14% of patients, in whom there
were drug-related adverse events of special interest, those
with potential immune-related causes; they included pneu-
monitis, vitiligo, colitis, hepatitis, hypophysitis and thyroi-
ditis. Pneumonitis (3%) ranged from isolated radiographic
abnormalities to progressive, diffuse infiltrates associated
with clinical symptoms in a small number of patients.
Although three deaths occurred, mild-to-moderate pneu-
monitis was managed successfully with either observation
or glucocorticoids. However, objective responses were
observed in approximately one in four to one in five
patients with non-small-cell lung cancer, melanoma, or
renal-cell cancer; overall, an adverse-event profile does not
appear to preclude its use [108]. Besides these studies, an
ongoing phase I safety trial with active hepatitis C geno-
type 1 infected patients has been designed to assess the
safety and tolerability profile of MDX-1106 [109]. Clinical
studies to evaluate the use of CT-011 in HCV disease have
also been initiated [110].
CTLA-4 is up-regulated on activated T cells and inhibits
T cell activation by reducing the production of IL-2 and
arresting cell cycle progression. CTLA-4 has also been
shown to have an impact on T cell responses in animal
tumor models and humans [111,112]. Human trials that
used a blocking anti-CTLA-4 mAb demonstrated a reduc-
tion in tumor mass and clinical benefit in a substantial
minority of treated subjects. Studies of the role for CTLA-
4 in chronic infections have produced mixed results. In
chronic HIV infection, many studies indicate that impaired
CD4+ T cell function is associated with viral persistence
[113], although the function of CTLA-4 in causing HIV
persistence by suppressing T cell function remains unclear
[114]. On the other hand, CTLA-4’s role in chronic HCV
infection seems to be more defined. The HCV-specific
CD8+ T cells found in the livers of chronic HCV patients
overexpressed not only PD-1, but also CTLA-4.
Co-expression of PD-1 and CTLA-4 was observed in liver-
infiltrating lymphocytes, but not in peripheral blood lym-
phocytes [36], suggesting the phenotypic differences of
virus-specific CD8+ T cells in different in vivo compart-
ments. PD-1 and CTLA-4 expressing HCV-specific T cells
were profoundly dysfunctional [115].
Tremelimumab is a fully human IgG2 mAb directed
against CTLA-4. While a phase II study for HIV disease
with this drug has been withdrawn prior to enrollment,
clinical trials for HCV disease are still underway. Tremeli-
mumab binds to activated T lymphocytes and results in
inhibition of B7-CTLA-4-mediated down-regulation of T-
cell activation. It also acts as an IL-2 stimulant. It was gen-
erated, using XenoMouse technology (Figure 2), as an
anticancer agent and is currently in worldwide phase
III development for malignant melanoma, phase II
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development for colorectal cancer, gastrointestinal cancer,
gynecological cancer and non-small cell lung cancer in the
US and other countries. It is also being investigated for
prostate, breast and pancreatic cancer in various countries.
As for anti-PD-1 antibodies, immune-related adverse
effects of tremelimumab are of special interest because of
its presumed mechanism of action. Most of the experience
in identifying and managing CTLA-4 treatment-related
side effects has derived from studies in cancer, particularly
in melanoma. These effects mainly include colitis/diarrhea,
dermatitis, hepatitis and endocrinopathies; uveitis, nephritis
and inflammatory myopathy also have been occasionally
reported. These unique side effects are likely a direct result
of breaking immune tolerance upon CTLA-4 blockade;
they are generally mild, reversible and manageable, follow-
ing specific treatment guidelines that include symptomatic
therapies or systemic corticosteroids [116]. In December
2008, Pfizer initiated a phase II trial in patients with late-
stage unresectable liver cancer who also have hepatitis C
infections. The primary endpoint of this single-armed
study is the ability of tremelimumab to produce tumor
responses among HCV-infected patients with hepatocellu-
lar carcinoma and to produce changes in hepatitis C viral
load. The first results indicate that tremelimumab demon-
strated an excellent safety profile, with a promising antitu-
mor efficacy against HCC in 17 patients, as well as an
intense antiviral activity. In fact, a significant and progres-
sive decline in serum HCV viral load was observed, this
being associated with an increase in anti-HCV immune
response in 76% of patients [117].
Since there are multiple levels of immunoregulation, a
synergistic use of antibodies against different checkpoint
molecules might represent the next stage in immunother-
apy for chronic infectious diseases, as evidenced from ex
vivo studies about the combined PD-1/CTLA-4 blockade
in HCV disease [36]. Furthermore, because the host
mechanisms that inhibit T cell activity are common and
conserved aside from specific virus-encoded immune eva-
sion strategies, the antibodies targeting inhibitory recep-
tors may prove extremely versatile drugs potentially
effective against multiple classes of viruses.
Conclusions
The need to treat HIV and HCV infectious diseases, two
epidemics of global impact, has reawakened interest in
mAb-based therapy, supporting a variety of clinical stu-
dies. The results that are emerging, will help to create
models for the further development of such drugs and
extend their use against other viruses as well.
Although the mAb production costs are high, increas-
ing advances of biotechnology and production systems
will make them more competitive on the market, and
new approaches, such as using mAb cocktails or combin-
ing mAbs with available drugs, will improve effectiveness.
Treatment with mAbs as part of a drug regimen is the
most likely future for mAbs that block HCV and HIV
infection in order to avoid viral escape, while chronic
treatment could attract further investments from phar-
maceutical companies. Furthermore, broad spectrum
mAbs, such as bavituximab and immunomodulatory
mAbs, could be useful against a whole range of diseases,
thus extending marketability and profit margins.
This review has focused on the use of intact mAbs as a
novel emerging and versatile class of pharmaceuticals. It is
important to note, however, that biotechnology also pro-
vides the opportunity to build various antibody formats
whose improved pharmacokinetics and pharmacodynamic
properties could be co-opted in the fight against infectious
diseases.
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